Wuhan Kangle Pharmaceutical Co., Ltd.

Wuhan Kangle Pharmaceutical Co., Ltd. was established in 1965. After withstanding the tide of state-owned enterprise reform, it has now developed into an industrial enterprise equipped with modern high-tech pharmaceutical technology, specializing in the research and development, production, and sales of traditional Chinese medicine. The company is located in the Wuhan Economic and Technological Development Zone and currently has ten dosage forms, including tablets, hard capsules, granules, decocted ointments, syrups, and mixtures, all of which passed the new GMP certification in 2015. It currently has 47 drug production approval numbers, of which 8 are national essential drugs and 18 are national medical insurance drugs. Its main products are traditional Chinese patent medicines such as Jianganle Granules, Qinglin Granules, Shenmai Granules, Qingwei Huanglian Tablets, and Shiquan Dabu Ointment. Among them, Jianganle Granules is an anti-inflammatory and liver-protective drug with remarkable efficacy and is the only nationally medical-insured product of its kind. The company has more than fifty years of experience in traditional Chinese patent medicine manufacturing. It upholds the corporate spirit of the Renfu Group — "innovation, realism, sincerity, perseverance, and unity" — and takes "inheriting and developing high-quality traditional Chinese patent medicines" as its mission!